Skip to main content

Table 2 Competing risks regression analysis with separate inclusion of the lymph node ratio (LNR) and pN stage as a covariate

From: The lymph node ratio predicts cancer-specific survival of node-positive non-small cell lung cancer patients: a population-based SEER analysis

Characteristics

SHR

P

SHR

P

LNR classification

 LNR1

1(Reference)

   

 LNR2

1.56 (1.47–1.67)

< 0.001

  

 LNR3

2.54 (2.30–2.80)

< 0.001

  

N stage

 N1

  

1 (Reference)

 

 N2

  

1.54 (1.45–1.63)

< 0.001

 N3

  

2.81 (2.32–3.41)

< 0.001

Sex

 Female

1(Reference)

 

1(Reference)

 

 Male

1.23 (1.16–1.30)

< 0.001

1.21 (1.134–1.29)

< 0.001

Race

 White

1(Reference)

 

1(Reference)

 

 Black

0.94 (0.85–1.05)

0.262

0.97 (0.87–1.07)

0.506

 Others

0.90 (0.81–1.00)

0.040

0.88 (0.79–0.98)

0.020

Primary site

 Upper lobe

1(Reference)

 

1(Reference)

 

 Lowerlobe

1.08 (1.01–1.15)

0.018

1.11 (1.04–1.18)

0.001

 Mainbronchus

1.20 (0.96–1.49)

0.103

1.21 (0.98–1.51)

0.083

 Middlelobe

0.93 (0.81–1.06)

0.290

1.03 (0.91–1.18)

0.625

 Overlapping/NOS

1.28 (1.10–1.49)

0.001

1.30 (1.12–1.52)

< 0.001

Grade

 I/II

1(Reference)

 

1(Reference)

 

 III/IV

1.23 (1.16–1.31)

< 0.001

1.25 (1.18–1.33)

< 0.001

Histology

 Adenocarcinoma

1(Reference)

 

1(Reference)

 

 Squamous

0.92 (0.86–0.99)

 

0.91 (0.84–0.97)

0.008

 Others

1.15 (1.05–1.25)

0.002

1.14 (1.04–1.24)

0.003

T stage

 

0.030

  

 T1

1(Reference)

   

 T2

1.32 (1.23–1.412)

< 0.001

1.29 (1.199–1.38)

< 0.001

 T3

1.85 (1.62–2.12)

< 0.001

1.78 (1.56–2.04)

< 0.001

 T4

1.82 (1.64–2.01)

< 0.001

1.82 (1.64–2.01)

< 0.001

  1. LNR Lymph node ratio, SHR sub-distribution hazards ratio